NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

These Analysts Revise Their Forecasts On Microchip Technology After Q3 Results

Published 02/02/2024, 13:47
Updated 02/02/2024, 15:10
© Reuters.  These Analysts Revise Their Forecasts On Microchip Technology After Q3 Results
MCHP
-

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

Microchip Technology Inc (NASDAQ: MCHP) reported upbeat earnings for its third quarter on Thursday.

Net sales of $1.766 billion, down 18.6% Y/Y, missing the consensus of $1.774 billion. Adjusted EPS was $1.08, beating the consensus of $1.04, according to data from Benzinga Pro.

Adjusted gross margin declined to 63.8% from 68.1%, and adjusted operating margin fell to $728.1 million (from $1.030 billion a year ago), with margins of 41.2% vs. 47.5% prior year quarter.

Ganesh Moorthy, President and Chief Executive Officer, said, “Our December quarter performance fell short of our November guidance, primarily due to weaker business conditions. Revenue declined 21.7% sequentially as weak demand drove customers to cut shipments and extend shutdowns to further de-risk their inventories, which prevented us from fulfilling previously planned shipments from backlog.”

For the fourth quarter, Microchip expects net sales of $1.225 billion-$1.425 billion (vs. consensus of $1.66 billion) and adjusted EPS of $0.46-$0.68 (vs. $0.91 estimate).

Microchip Technology shares gained 0.6% to close at $85.65 on Thursday.

These analysts made changes to their price targets on Microchip Technology after the company reported quarterly results.

  • Needham raised the price target on Microchip Technology from $85 to $90. Needham analyst Quinn Bolton maintained a Buy rating.
  • Susquehanna cut Microchip Technology price target from $105 to $100. Susquehanna analyst Christopher Rolland maintained a Positive rating.

Read This Next: Amazon, Apple And 3 Stocks To Watch Heading Into Friday

Latest Ratings for MCHP

DateFirmActionFromTo
Mar 2022UBSMaintainsBuy
Feb 2022RosenblattMaintainsBuy
Jan 2022UBSUpgradesNeutralBuy
View More Analyst Ratings for MCHP

View the Latest Analyst Ratings

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.